Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F20%3AN0000031" target="_blank" >RIV/00064190:_____/20:N0000031 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/s10557-020-07095-6" target="_blank" >http://dx.doi.org/10.1007/s10557-020-07095-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10557-020-07095-6" target="_blank" >10.1007/s10557-020-07095-6</a>
Alternative languages
Result language
angličtina
Original language name
Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry
Original language description
Purpose This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). Methods Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (>= 6 months to < 2 years after hospitalization) was collected. Results Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%;P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%;P < 0.001) and calcium channel blockers (21.2% vs. 28.8%;P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%;P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%;P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. Conclusion The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/NV17-29520A" target="_blank" >NV17-29520A: Long term trends of CHD secondary prevention and risk prediction in selected sample of Czech population – Czech part of the EUROASPIRE V Study</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
CARDIOVASCULAR DRUGS AND THERAPY
ISSN
0920-3206
e-ISSN
1573-7241
Volume of the periodical
35
Issue of the periodical within the volume
4
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
8
Pages from-to
801-808
UT code for WoS article
000579030000001
EID of the result in the Scopus database
2-s2.0-85092791964